Author: tianli

Upadhyay, Neha;Tilekar, Kalpana;Safuan, Sabreena;Kumar, Alan P.;Schweipert, Markus;Meyer-Almes, Franz-Josef;Ramaa, Cs published 《Development and investigation of thiazolidinedione and pyrazoline compounds as antiangiogenic weapons targeting VEGFR-2》 in 2021. The article was appeared in 《Future Medicinal Chemistry》. They have made some progress in their research.Category: thiazole The article mentions the following:

Angiogenesis deregulation is often linked to cancer and is thus an essential target. Twenty-nine compounds were developed as VEGFR-2 inhibitors. Compounds were evaluated to determine their antiangiogenic activity. B1, PB11 and PB16 showed HUVEC′s IC₅₀ scores in the submicromolar range. B1, B2 and PB16 reduced cellular migration and capillary tube formation of HUVECs. VEGFR-2 inhibitory activity was found in the nanomolar range: 200 nM of B1, 500 nM of B2 and 600 nM of PB16. B1 and PB16 suppressed the formation of new capillaries on growing CAMs. B1 and PB16 occupied the ATP site and allosteric pocket of VEGFR-2 in docking studies. These compounds can target VEGFR-2 and are endowed with in vitro and in vivo antiangiogenic activity. The experimental procedure involved many compounds, such as 6-Nitrobenzo[d]thiazol-2-amine (cas: 6285-57-0) .

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0 Category: thiazole) inhibits the activity of amines, which are small molecules found in many pharmaceuticals. The chemical structure of this drug contains one or more methylene groups that can be activated by diazonium salt to form an intermediate molecule with a reactive amine group.

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Smith, Tania;Hoyo-Vadillo, Carlos;Adom, Akosua Agyeman;Favari-Perozzi, Liliana;Gastine, Silke;Dehbi, Hakim-Moulay;Villegas-Lara, Beatriz;Mateos, Eduardo;Gonzalez, Yessica Sara Perez;Navarro-Gualito, Maria D.;Cruz-Carbajal, Alejandra S.;Cortes-Vazquez, Miguel A.;Bekker-Mendez, Carolina;Aguirre-Alvarado, Charmina;Aguirre-Gil, Gisela;Delgado-Pastelin, Lucero;Owen, Andrew;Lowe, David;Standing, Joseph;Escobedo, Jorge published 《Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)》 in 2022. The article was appeared in 《Trials》. They have made some progress in their research.Formula: C12H9N3O5S The article mentions the following:

Abstract: Background: The 2020 pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emergency. COVID-19 appears to be a disease with an early phase where the virus replicates, coinciding with the first presentation of symptoms, followed by a later ′inflammatory′ phase which results in severe disease in some individuals. It is known from other rapidly progressive infections such as sepsis and influenza that early treatment with antimicrobials is associated with a better outcome. The hypothesis is that this holds for COVID-19 and that early antiviral treatment may prevent progression to the later phase of the disease. Methods: Trial design: Phase IIA randomised, double-blind, 2 x 2 design, placebo-controlled, interventional trial. Randomisation: Participants will be randomised 1:1 by stratification, with the following factors: gender, obesity, symptomatic or asymptomatic, current smoking status presence or absence of comorbidity, and if the participant has or has not been vaccinated. Blinding: Participants and investigators will both be blinded to treatment allocation (double-blind). Discussion: We propose to conduct a proof-of-principle placebo-controlled clin. trial of favipiravir plus or minus nitazoxanide in health workers, their household members and patients treated at the Mexican Social Security Institute (IMSS) facilities. Participants with or without symptomatic COVID-19 or who tested pos. will be assigned to receive favipiravir plus nitazoxanide or favipiravir plus nitazoxanide placebo. The primary outcome will be the difference in the amount of virus (′viral load′) in the upper respiratory tract after 5 days of therapy. Secondary outcomes will include hospitalization, major morbidity and mortality, pharmacokinetics, and impact of antiviral therapy on viral genetic mutation rate. If favipiravir with nitazoxanide demonstrates important antiviral effects without significant toxicity, there will be a strong case for a larger trial in people at high risk of hospitalization or intensive care admission, for example older patients and/or those with comorbidities and with early disease. Trial registration: ClinicalTrials.govNCT04918927. Registered on June 9, 2021. And 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) was used in the research process.

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4), a thiazolide compound, is a antiparasitic drug with structure similar to niclosamide.Formula: C12H9N3O5S

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Name: 6-Nitrobenzo[d]thiazol-2-amine《Lemon juice mediated multicomponent reactions for the synthesis of fused imidazoles》 was published in 2018. The authors were Saha, Argha;Jana, Asim;Choudhury, Lokman H., and the article was included in《New Journal of Chemistry》. The author mentioned the following in the article:

A one-pot three component reaction mediated by lemon juice in an aqueous medium for the synthesis of diverse pharmaceutically important tricyclic fused imidazoles tethered with aryl and various cyclic 1,3-dicarbonyls was reported. The reaction of arylglyoxals with cyclic 1,3-diacarbonyls such as N-methyl-4-hydroxyquinolone, 2,4-dihydroxyquinoline, 4-hydroxycoumarin or 4-hydroxy-6-methyl-2-pyrone with various 1,3-N,N-binucleophiles such as 2-aminobenzothiazoles or 2-aminobenzimidazoles provided medicinally important diverse tricyclic fused imidazoles having aryl and cyclic 1,3-dicarbonyl substituents under metal-free conditions. This method is a natural acid catalyzed multicomponent reaction in an aqueous medium for the synthesis of diverse tricyclic fused imidazoles in good to excellent yields.6-Nitrobenzo[d]thiazol-2-amine (cas: 6285-57-0) were involved in the experimental procedure.

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0 Name: 6-Nitrobenzo[d]thiazol-2-amine) is an antimicrobial agent that inhibits bacterial growth by cleaving the peptide bonds of proteins. It has been shown to be active against a number of microorganisms, including Gram-positive and Gram-negative bacteria, as well as fungi.

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Related Products of 6285-57-0《Synthesis and Characterization of Soluble Aromatic Polyesters with Side-Chain Azobeneze and Azothiazole Chromophores》 was published in 2018. The authors were Asgari, Shadi;Koohmareh, Gholam Ali;Parsanasab, Gholam Mohammad, and the article was included in《Polymer Science, Series B: Polymer Chemistry》. The author mentioned the following in the article:

The paper presents the synthesis of a series of polyesters containing nitro-substituted Ph azothiazole, azobenzothiazole and azobenzene chromophores and their characterization by ¹H NMR, FTIR and UV-Vis spectroscopy. Also the solubility, glass transition temperatures, thermal stability of the synthesized polyesters as well as the surface morphol. of thin films of the polyesters were studied. To complete the study, the researchers used 6-Nitrobenzo[d]thiazol-2-amine (cas: 6285-57-0) .

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0 Related Products of 6285-57-0) is an antimicrobial agent that inhibits bacterial growth by cleaving the peptide bonds of proteins. It has been shown to be active against a number of microorganisms, including Gram-positive and Gram-negative bacteria, as well as fungi.

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Wu, Yue;Guo, Peng;Chen, Long;Duan, Weijie;Yang, Zengzhuan;Wang, Tao;Chen, Ting;Xiong, Fei published 《Iron-catalyzed tandem oxidative coupling and acetal hydrolysis reaction to prepare formylated benzothiazoles and isoquinolines》 in 2021. The article was appeared in 《Chemical Communications (Cambridge, United Kingdom)》. They have made some progress in their research.Recommanded Product: 6-Nitrobenzo[d]thiazol-2-amine The article mentions the following:

The direct formylation of benzothiazoles and isoquinolines was reported. The reaction features a novel iron-catalyzed Minisci-type oxidative coupling process using com. available 1,3-dioxolane as a formylated reagent followed by acetal hydrolysis without a separation process. The reaction was performed under exceedingly mild reaction conditions and exhibited broad functional group tolerance. The experimental procedure involved many compounds, such as 6-Nitrobenzo[d]thiazol-2-amine (cas: 6285-57-0) .

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0Recommanded Product: 6-Nitrobenzo[d]thiazol-2-amine) has been shown to lower blood pressure in mice by inhibiting angiotensin converting enzyme and potassium channels. This drug also has a protective effect on the heart and brain from ischemia reperfusion injury.

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Application In Synthesis of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate《Current pharmacotherapy of cryptosporidiosis: an update of the state-of-the-art》 was published in 2021. The authors were Schneider, Anne;Wendt, Sebastian;Luebbert, Christoph;Trawinski, Henning, and the article was included in《Expert Opinion on Pharmacotherapy》. The author mentioned the following in the article:

Cryptosporidiosis has emerged as a major cause of diarrheal disease worldwide. It has especially serious health consequences for young, malnourished children living in endemic areas and for individuals with highly impaired T-cell function, such as HIV-pos. individuals with low CD4 counts or immunosuppressed solid-organ transplant recipients. A selective literature search using PubMed was performed to review the available therapeutics to treat cryptosporidiosis, as well as related advances in drug development. The only FDA-approved antiparasitic treatment in immunocompetent patients is nitazoxanide; however, it has failed to demonstrate convincing effectiveness among HIV-pos. patients, immunosuppressed individuals and malnourished children. Thus, restoring HIV-pos. patients’ cellular immune response through effective antiretroviral therapy (ART), or reducing or changing immunosuppressive drugs, is important. Several new targets have been identified for chemotherapy, and the development of drugs for these targets has progressed, including parasite kinases, nucleic acid synthesis and processing, proteases and lipid metabolism Candidate drugs that have been shown to be effective and safe in a neonatal calf model will most likely constitute the next advance for clin. trials in humans. However, developing an effective and inexpensive vaccination, as well as complementing structural preventive measures, would most decisively reduce the global cryptosporidiosis burden. And 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) was used in the research process.

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4) has been approved as an orphan drug for the treatment of diarrhea in children (age, 1–11 years) and is associated with giardiasis, but it also is approved for diarrhea caused by crytosporidiosis in patients with AIDS.Application In Synthesis of 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Name: 6-Nitrobenzo[d]thiazol-2-amineIn 2022, Sheetal;Sengupta, Sirsendu;Singh, Manjeet;Thakur, Sanjeeve;Pani, Balaram;Banerjee, Priyabrata;Kaya, Savas;Singh, Ashish Kumar published 《An insight about the interaction of Aryl Benzothiazoles with mild steel surface in aqueous HCl solution》. 《Journal of Molecular Liquids》published the findings. The article contains the following contents:

The arrival of organic moieties as corrosion inhibitors has expanded the research in the past few years which, as a result; involved different heteroatoms to be tested for their anti-corrosive potential. The presented research is focused on the synthesis of the aryl-substituted benzothiazoles namely 6-(4-Chlorophenyl) benzo[d]thiazol-2-amine (CBTA), 6-(p-tolyl) benzo[d]thiazol-2-amine (TBTA), and 6-(4-methoxyphenyl) benzo[d]thiazol-2-amine (MBTA), and investigation of their anti-corrosive behavior on mild steel in 1 M HCl particularly. Here, gravimetric and electrochem. analyses have been employed to examine the tendency of benzothiazoles to safeguard mild steel. Corrosion impeding efficacies were found to follow a significant order; MBTA > TBTA > CBTA. Further, exptl. anal. unveiled the effect of substituents on corrosion mitigating potential i.e., MBTA employed the ligation of methoxy group; an enhanced electron cloud thus providing a maximum shield. The addition of corrosion inhibitors in acidic solution brought an elevation in activation energy thus retarded the rate of corrosion. Surface anal. via at. force microscopy (AFM) and XPS confirmed the exptl. results and attributed the presence of an adsorbed layer over mild steel surface thus providing protection from corrosion. Addnl., Quantum calculations such as d. functional theory (DFT) and mol. dynamics (MD) provided an insight into the adsorption of inhibitors over mild steel at a mol. level. The experimental procedure involved many compounds, such as 6-Nitrobenzo[d]thiazol-2-amine (cas: 6285-57-0) .

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0 Name: 6-Nitrobenzo[d]thiazol-2-amine) inhibits the activity of amines, which are small molecules found in many pharmaceuticals. The chemical structure of this drug contains one or more methylene groups that can be activated by diazonium salt to form an intermediate molecule with a reactive amine group.

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Goel, Vasudha;Jain, Anubhav;Sharma, Garima;Jhajharia, Ashok;Agarwal, Vishnu Kumar;Ashdhir, Prachis;Pokharna, Rupesh;Chauhan, Virender published 《Evaluating the efficacy of nitazoxanide in uncomplicated amebic liver abscess.》. The research results were published in《Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology》 in 2021.HPLC of Formula: 55981-09-4 The article conveys some information:

BACKGROUND: Amebic liver abscess is treated successfully with metronidazole or another nitroimidazole drug followed by a luminal amebicide. Metronidazole has long been preferred, but has been associated with several adverse effects including intolerance in certain clinical situations. Mechanisms of metronidazole resistance and mutagenic potential have been described. Effects of the use of drug in pregnant women and infants of lactating women are unknown. Nitazoxanide was proven to be efficacious in treating invasive intestinal amebiasis. Therefore, the present study was undertaken to assess the efficacy and safety of nitazoxanide as compared to metronidazole in patients with uncomplicated amebic liver abscess. METHODS: Patients with clinical and ultrasonography features suggestive of liver abscess, positive amebic serology, and/or anchovy sauce appearance on aspiration of the pus were included in the study and randomized into two parallel treatment groups. Group M received metronidazole, 2-2.5 g/day intravenous (IV), for inpatients, or 2-2.4 g/day oral, for outpatients in three divided doses for 14 days. Group N received nitazoxanide 500 mg BD per oral for 10 days. RESULTS: A total of sixty subjects fulfilling the inclusion criteria were randomized equally into two groups, group M and group N. Number of patients achieving symptomatic clinical response (SCR) was similar in the two groups (80% vs. 76.7%, p = 1.00), though time to achieve symptomatic clinical response was significantly lower in metronidazole group as compared to that in nitazoxanide group. Greater proportion of patients achieved early clinical response (ECR) in metronidazole group as compared to nitazoxanide group. Complete resolution of abscess, at 6 months, was noted in 18 (60%) patients in the M group and 22 (73.3%) patients in the N group (p = 0.273). Metronidazole was associated with significantly greater frequency of adverse effects than nitazoxanide. CONCLUSIONS: This study shows equivalent efficacy of nitazoxanide in uncomplicated amebic liver abscess as compared to metronidazole, with better tolerability and advantage of simultaneous luminal clearance, thus reducing chances of recurrence. TRIAL REGISTRATION: CTRI/2019/01/017249. To complete the study, the researchers used 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) .

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4), a thiazolide compound, is a antiparasitic drug with structure similar to niclosamide.HPLC of Formula: 55981-09-4

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Pisal, Pooja;Deodhar, Meenakshi;Kale, Amol;Nigade, Ganesh;Pawar, Smita published 《Design, synthesis, docking studies and biological evaluation of 2-phenyl-3-(substituted benzo[d]thiazol-2-ylamino)-quinazoline-4(3H)-one derivatives as antimicrobial agents》. The research results were published in《International Journal of Pharmacy and Pharmaceutical Sciences》 in 2018.COA of Formula: C7H5N3O2S The article conveys some information:

A new series 2-phenyl-3-(substituted benzo[d] thiazol-2-ylamino)-quinazoline-4(3H)-ones, compounds I [R = H, Cl, MeO, etc.] was prepared by the fusion method by reacting 2-Ph benzoxazine with 2-hydrazinobenzothiazole and it was evaluated for their antimicrobial activity against Gram pos., Gram neg. bacteria and fungi. These compounds were evaluated by in-vitro antibacterial and antifungal activity using the min. inhibitory concentration and zone of inhibition methods. The synthesized compounds were characterized with the help of IR, NMR and mass spectral studies. The benzothiazole moiety and the quinazoline ring have previously shown DNA gyrase inhibition and target related antibacterial activity. Thus, mol. docking studies of synthesized compounds were carried out (PDB: 3G75) to study the possible interaction of compounds with the target. The batch grid docking was performed to determine the probable. These compounds showed significant activity against gram pos. and gram neg. bacteria as well against the fungi. Compound I [R = NO₂] was found to be active against B. subtilis, P aeruginosa and C. albicans at 12.5 μg/mL MIC. Compound I [R = Cl] was found to be active against all microbial strains selected at 25 and 12.5 μg/mL MIC. Though the relationship between the activities shown by these compounds in, the antimicrobial study is still to be established, the docking studies conducted found to be consistent with antimicrobial results. Thus the results indicate that the designed structure can be a potential lead as an antimicrobial agent. And 6-Nitrobenzo[d]thiazol-2-amine (cas: 6285-57-0) was used in the research process.

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0 COA of Formula: C7H5N3O2S) is an antimicrobial agent that inhibits bacterial growth by cleaving the peptide bonds of proteins. It has been shown to be active against a number of microorganisms, including Gram-positive and Gram-negative bacteria, as well as fungi.

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica